LEAP FORWARD: Innovate Faster (#1)
Thursday, April 22, 2021 (12:00 PM - 1:30 PM) (EDT)
Description
The 2021 European-American Business Trends Series by LEAP-Atlantic will virtually gather executives from both sides of the Atlantic for three insightful and timely discussions around some of the most pertinent themes in European-American business community today.
April 22, 2021: #1 INNOVATE FASTER
Innovation in the digital realm has been a leading driver of European and American economies while transatlantic technology investment is giving rise to not only start-ups, but to global market leaders. In this panel, we will identify how successful transatlantic ventures are achieving success and hear from experts on opportunities for additional cross-border investment. More details & line up of speakers available soon.
Interested in sponsorship or speaker opportunities?
About LEAP-Atlantic
BelCham is excited to unveil a brand new brand and energy between the group of 20 bi-national chambers: LEAP Atlantic (formerly known as EACC). LEAP Atlantic is the world’s largest dynamic collective of business experts, entrepreneurs and thought leaders, offering unparalleled growth and partnership opportunities between European and American organizations.
Save the date for the second and third part in this series
May 6, 2021: #2 (RE)BUILD SMARTER
While the world’s demand for energy and clean water continue to grow alongside greenhouse gases, companies throughout Europe and the United States are devising innovative solutions to address these global concerns. With the United States back among Paris accord signatories, the transatlantic relationship will be key force to developing and implementing financially viable sustainability models.
May 27, 2021: #3 LIVE HEALTHIER
Biotechnology, gene therapy and the use of artificial intelligence are changing the face of healthcare, with European and American firms at the forefront of research, development, and commercialization. Start-up ventures now compete around the world with entrenched players to develop the next lifesaving treatment. Policy and ethical issues are stirring considerable debate in European-American life sciences circles, while many are seeing investment opportunities that attract global capital.